These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 31639138)

  • 1. Analysis of determinants for in vitro resistance to the small molecule deubiquitinase inhibitor b-AP15.
    Mofers A; Perego P; Selvaraju K; Gatti L; Gullbo J; Linder S; D'Arcy P
    PLoS One; 2019; 14(10):e0223807. PubMed ID: 31639138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The proteasome deubiquitinase inhibitor VLX1570 shows selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma cells.
    Wang X; Mazurkiewicz M; Hillert EK; Olofsson MH; Pierrou S; Hillertz P; Gullbo J; Selvaraju K; Paulus A; Akhtar S; Bossler F; Khan AC; Linder S; D'Arcy P
    Sci Rep; 2016 Jun; 6():26979. PubMed ID: 27264969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and evaluation of derivatives of the proteasome deubiquitinase inhibitor b-AP15.
    Wang X; D'Arcy P; Caulfield TR; Paulus A; Chitta K; Mohanty C; Gullbo J; Chanan-Khan A; Linder S
    Chem Biol Drug Des; 2015 Nov; 86(5):1036-48. PubMed ID: 25854145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance.
    Tian Z; D'Arcy P; Wang X; Ray A; Tai YT; Hu Y; Carrasco RD; Richardson P; Linder S; Chauhan D; Anderson KC
    Blood; 2014 Jan; 123(5):706-16. PubMed ID: 24319254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of ER Stress in Acute Lymphoblastic Leukemia Cells by the Deubiquitinase Inhibitor VLX1570.
    Pellegrini P; Selvaraju K; Faustini E; Mofers A; Zhang X; Ternerot J; Schubert A; Linder S; D Arcy P
    Int J Mol Sci; 2020 Jul; 21(13):. PubMed ID: 32635430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coinhibition of the deubiquitinating enzymes, USP14 and UCHL5, with VLX1570 is lethal to ibrutinib- or bortezomib-resistant Waldenstrom macroglobulinemia tumor cells.
    Paulus A; Akhtar S; Caulfield TR; Samuel K; Yousaf H; Bashir Y; Paulus SM; Tran D; Hudec R; Cogen D; Jiang J; Edenfield B; Novak A; Ansell SM; Witzig T; Martin P; Coleman M; Roy V; Ailawadhi S; Chitta K; Linder S; Chanan-Khan A
    Blood Cancer J; 2016 Nov; 6(11):e492. PubMed ID: 27813535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting proteasomal deubiquitinases USP14 and UCHL5 with b-AP15 reduces 5-fluorouracil resistance in colorectal cancer cells.
    Ding W; Wang JX; Wu JZ; Liu AC; Jiang LL; Zhang HC; Meng Y; Liu BY; Peng GJ; Lou EZ; Mao Q; Zhou H; Tang DL; Chen X; Liu JB; Shi XP
    Acta Pharmacol Sin; 2023 Dec; 44(12):2537-2548. PubMed ID: 37528233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted inhibition of the deubiquitinating enzymes, USP14 and UCHL5, induces proteotoxic stress and apoptosis in Waldenström macroglobulinaemia tumour cells.
    Chitta K; Paulus A; Akhtar S; Blake MK; Caulfield TR; Novak AJ; Ansell SM; Advani P; Ailawadhi S; Sher T; Linder S; Chanan-Khan A
    Br J Haematol; 2015 May; 169(3):377-90. PubMed ID: 25691154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteasomal cysteine deubiquitinase inhibitor b-AP15 suppresses migration and induces apoptosis in diffuse large B cell lymphoma.
    Jiang L; Sun Y; Wang J; He Q; Chen X; Lan X; Chen J; Dou QP; Shi X; Liu J
    J Exp Clin Cancer Res; 2019 Nov; 38(1):453. PubMed ID: 31694672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Deubiquitinase Inhibitor b-AP15 and Its Effect on Phenotype and Function of Monocyte-Derived Dendritic Cells.
    Schmidt M; Altdörfer V; Schnitte S; Fuchs AR; Kropp KN; Maurer S; Müller MR; Salih HR; Rittig SM; Grünebach F; Dörfel D
    Neoplasia; 2019 Jul; 21(7):653-664. PubMed ID: 31132676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of tumor cell apoptosis by a proteasome deubiquitinase inhibitor is associated with oxidative stress.
    Brnjic S; Mazurkiewicz M; Fryknäs M; Sun C; Zhang X; Larsson R; D'Arcy P; Linder S
    Antioxid Redox Signal; 2014 Dec; 21(17):2271-85. PubMed ID: 24011031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute lymphoblastic leukemia cells are sensitive to disturbances in protein homeostasis induced by proteasome deubiquitinase inhibition.
    Mazurkiewicz M; Hillert EK; Wang X; Pellegrini P; Olofsson MH; Selvaraju K; D'Arcy P; Linder S
    Oncotarget; 2017 Mar; 8(13):21115-21127. PubMed ID: 28423502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The 19S Deubiquitinase inhibitor b-AP15 is enriched in cells and elicits rapid commitment to cell death.
    Wang X; Stafford W; Mazurkiewicz M; Fryknäs M; Brjnic S; Zhang X; Gullbo J; Larsson R; Arnér ES; D'Arcy P; Linder S
    Mol Pharmacol; 2014 Jun; 85(6):932-45. PubMed ID: 24714215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteasome inhibitor b-AP15 induces enhanced proteotoxicity by inhibiting cytoprotective aggresome formation.
    Hillert EK; Brnjic S; Zhang X; Mazurkiewicz M; Saei AA; Mofers A; Selvaraju K; Zubarev R; Linder S; D'Arcy P
    Cancer Lett; 2019 Apr; 448():70-83. PubMed ID: 30768956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteasome deubiquitinases as novel targets for cancer therapy.
    D'Arcy P; Linder S
    Int J Biochem Cell Biol; 2012 Nov; 44(11):1729-38. PubMed ID: 22819849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of proteasome deubiquitinating activity as a new cancer therapy.
    D'Arcy P; Brnjic S; Olofsson MH; Fryknäs M; Lindsten K; De Cesare M; Perego P; Sadeghi B; Hassan M; Larsson R; Linder S
    Nat Med; 2011 Nov; 17(12):1636-40. PubMed ID: 22057347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma.
    Rowinsky EK; Paner A; Berdeja JG; Paba-Prada C; Venugopal P; Porkka K; Gullbo J; Linder S; Loskog A; Richardson PG; Landgren O
    Invest New Drugs; 2020 Oct; 38(5):1448-1453. PubMed ID: 32125598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repurposing of auranofin: Thioredoxin reductase remains a primary target of the drug.
    Zhang X; Selvaraju K; Saei AA; D'Arcy P; Zubarev RA; Arnér ES; Linder S
    Biochimie; 2019 Jul; 162():46-54. PubMed ID: 30946948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel deubiquitinase inhibitor b-AP15 triggers apoptosis in both androgen receptor-dependent and -independent prostate cancers.
    Cai J; Xia X; Liao Y; Liu N; Guo Z; Chen J; Yang L; Long H; Yang Q; Zhang X; Xiao L; Wang X; Huang H; Liu J
    Oncotarget; 2017 Sep; 8(38):63232-63246. PubMed ID: 28968984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The deubiquitinase inhibitor b-AP15 induces strong proteotoxic stress and mitochondrial damage.
    Zhang X; Pellegrini P; Saei AA; Hillert EK; Mazurkiewicz M; Olofsson MH; Zubarev RA; D'Arcy P; Linder S
    Biochem Pharmacol; 2018 Oct; 156():291-301. PubMed ID: 30149015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.